Hancock Jaffe Laboratories, Inc. (HJLI)
| Market Cap | 19.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.08M |
| Shares Out | 1.45M |
| EPS (ttm) | -7.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $8.54 |
| Previous Close | $9.09 |
| Change ($) | -0.55 |
| Change (%) | -6.05% |
| Day's Open | 9.05 |
| Day's Range | 8.26 - 9.01 |
| Day's Volume | 286,388 |
| 52-Week Range | 6.75 - 18.81 |
News
There are no news available yet.
About HJLI
Hancock Jaffe Laboratories, a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to... [Read more...]
| Industry Medical Devices | Founded 1987 |
| CEO Robert A. Berman | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol HJLI |
Financial Performance
In 2019, HJLI's revenue was $31,243, a decrease of -83.25% compared to the previous year's $186,552. Losses were -$7.63 million, -41.54% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for HJLI stock is "Strong Buy" and the 12-month stock price forecast is 26.25.